Cells harboring the BRAFV600E mutation experience persistent activation of the BRAF kinase, leading to continuous and autonomous stimulation of the MAPK pathway, even in the absence of extracellular ligands, contributing to the pathogenesis of thyroid carcinoma [2,55]. This evidence concerns the gene BRAF and thyroid gland carcinoma.